CVE-2026-21997: Oracle Life Sciences Empirica Signal · Improper Access Control
Affects Oracle Life Sciences Empirica SignalSource CVE Database V5
Not known to be exploited · CVSS 8.5 High.
Data as of 30 Oct 2026, 06:59 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 10% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:H/A:NExploitation evidence
Disclosed: evidence found.
CVE published 21 Apr 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 29 Oct 2026.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| Oracle CorporationOracle Life Sciences Empirica Signal | Affected
| Fixed in– |
AI-suggested
Oracle's April 2026 Critical Patch Update advisory strongly recommends applying the provided security patches without delay. Although no explicit patch availability or remediation level is stated for Oracle Life Sciences Empirica Signal in the advisory content, customers should monitor the referenced advisory and Oracle support channels for patch releases and installation instructions. Maintaining actively supported versions and promptly applying Critical Patch Updates is the primary mitigation.
Description
CVE-2026-21997 is a high-severity vulnerability in Oracle Life Sciences Empirica Signal versions 9.2.1 to 9.2.3. It allows a low privileged attacker with network access via HTTP to compromise the product, potentially impacting additional Oracle products. Successful exploitation can lead to unauthorized creation, deletion, or modification of critical data, as well as unauthorized read access to some data. The vulnerability has a CVSS 3.1 base score of 8.5, indicating significant confidentiality and integrity impacts.